The casein kinase 1 delta (CSNK1D) antibody is a research tool targeting the CSNK1D protein, a serine/threonine kinase belonging to the casein kinase 1 (CK1) family. CSNK1D plays critical roles in diverse cellular processes, including circadian rhythm regulation, Wnt and Hedgehog signaling pathways, DNA repair, and cell cycle progression. Its activity is tightly controlled through phosphorylation and subcellular localization. Dysregulation of CSNK1D has been linked to multiple diseases, such as cancer (e.g., breast, lung, and leukemia), neurodegenerative disorders (e.g., Alzheimer's and Parkinson’s), and sleep phase disorders due to its circadian functions.
Antibodies against CSNK1D are widely used in Western blotting, immunohistochemistry, and immunofluorescence to study its expression patterns, post-translational modifications, and interactions with signaling partners. They help elucidate CSNK1D's role in pathological conditions and its potential as a therapeutic target. For instance, small-molecule inhibitors of CSNK1D are under investigation for cancer and circadian-related therapies. Researchers also utilize these antibodies to validate CRISPR/Cas9 knockout models or assess drug efficacy in preclinical studies. Commercial CSNK1D antibodies are typically validated for specificity across human, mouse, and rat samples, with applications spanning basic research and drug development pipelines.